A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

The reason a price cap is being targeted is due to the ... The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart ...

Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

Telehealth platform GoodRx has become the latest company to offer people with diabetes access to insulin for $35 per month— regardless of whether they have insurance. GoodRx said in a statement ...